Free tool · No account
Clinical trials for leukemia
Leukemia covers several very different diseases (AML, ALL, CLL, CML), each with its own trials. Naming the specific type, and any known genetic marker, makes the search far more useful.
1,401 recruiting trials. Showing a sample.
- recruitingPhase 1, Phase 2NCT06561152
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.
Listed by the study for Refractory Acute Myeloid Leukemia. Record updated 2026-04-14.
Sponsored by Stanford UniversityFull details on ClinicalTrials.gov → - recruitingNANCT07313878
Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy
With increasing survival rates in pediatric oncology, reports of long-term side effects persisting decades after treatment are also rising. Clinically evident nephropathies occur in about 5.5% of survivors more than five years after therapy. Chemotherapeutic agents such as ifo...
Listed by the study for Acute Lymphoblastic Leukaemias (ALL). Record updated 2026-01-02.
Sponsored by University of Erlangen-Nürnberg Medical SchoolFull details on ClinicalTrials.gov → - recruitingPhase 1NCT05581030
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.
Listed by the study for Acute Lymphoblastic Leukemia. Record updated 2026-03-06.
Sponsored by H. Lee Moffitt Cancer Center and Research InstituteFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT07646821
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations
To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations. To learn if the recommended dose of ropeinterferon alfa-2b found in Dose Escalation in combination with azacitidine can help to...
Listed by the study for MDS/AML. Record updated 2026-10-16.
Sponsored by M.D. Anderson Cancer CenterFull details on ClinicalTrials.gov → - recruitingPhase 2NCT07605416
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
This phase II trial compares standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone to consolidation with teclistamab following standard induction therapy and autologous hematopoietic stem cell transplant for improving overall survival of patient...
Listed by the study for Plasma Cell Leukemia. Record updated 2026-10-26.
Sponsored by National Cancer Institute (NCI)Full details on ClinicalTrials.gov → - recruitingPhase 1NCT05735184
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC)...
Listed by the study for Acute Myeloid Leukemia. Record updated 2026-03-13.
Sponsored by Kura Oncology, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT06680752
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Listed by the study for Acute Myeloid Leukemia, in Relapse. Record updated 2025-12-10.
Sponsored by ARCE Therapeutics, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 3NCT07075016
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
The standard treatment for patients with acute myeloid leukemia (AML) with an abnormality in the IDH1 gene, who are not eligible for intensive chemotherapy, is a combination of ivosidenib and azacitidine. In this study it is investigated whether adding venetoclax to the standa...
Listed by the study for Acute Myeloid Leukemia. Record updated 2025-08-19.
Sponsored by Stichting Hemato-Oncologie voor Volwassenen NederlandFull details on ClinicalTrials.gov → - recruitingPhase 2NCT04838041
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI). All pa...
Listed by the study for Chronic Phase Chronic Myelogenous Leukemia. Record updated 2026-08-25.
Sponsored by Medical College of WisconsinFull details on ClinicalTrials.gov → - recruitingNANCT07131059
MRD-positive AML Clinical Study
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small mole...
Listed by the study for AML, Adult. Record updated 2026-08-10.
Sponsored by Institute of Hematology & Blood Diseases Hospital, ChinaFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-11-14. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this leukemia trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.